The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 801 Mounjaro articles
Ozempic, the blockbuster semaglutide drug from Novo Nordisk, is set to go generic in India as early as this weekend, with China, Brazil, Turkey, and South Africa following. This could drop prices to $15 per month, opening access to millions with obesity and diabetes. Meanwhile, U.S. and Europe face delays until 2030 due to patent extensions.
Reality star Layla Taylor shares her concerning experience obtaining a GLP-1 prescription with alarming ease in Utah, revealing how the medication became an 'unhealthy crutch' amid her long-term battle with an eating disorder. Her story highlights critical gaps in patient screening and mental health considerations.
More people are using GLP-1 injectables like Wegovy for weight management, but air travel poses refrigeration challenges. As a flight attendant, I've fielded countless requests to store meds in plane fridges—here's why that's not possible and the practical solutions that work.
High demand for GLP-1 medications meets steep pricing and insurance hurdles. In this Q&A, eHealth's Whitney Stidom reveals why 55% of employers cover GLP-1s for diabetes but only 36% for weight loss, plus upcoming policy changes capping costs at $245 monthly for Medicare enrollees. Discover actionable insights on affordability and access.
Weight loss drugs like Ozempic are transforming bodies, but dentists are sounding the alarm on 'Ozempic teeth'—a pattern of dry mouth, tooth sensitivity, and gum problems. Lt. Gen Dr Vimal Arora of Clove Dental notes increased xerostomia, dental caries, and early periodontal inflammation among users. Discover why this happens and steps to safeguard your smile.
GLP-1 therapies, including Ozempic (semaglutide) and Mounjaro (tirzepatide), have evolved from diabetes treatments to versatile options for weight management and cardiovascular health. While offering significant benefits like reduced appetite and vascular protection, they come with gastrointestinal side effects and rare serious risks. This guide evaluates their risks and rewards across conditions.
Telangana's Drugs Control Administration has issued a stark warning against misusing Semaglutide formulations for weight loss without medical oversight. With patent expiry looming in March 2026, multiple versions are flooding the market, raising safety concerns. Improper use risks serious complications like pancreatitis and gastrointestinal disorders.
India's DCGI is cracking down harder on the unauthorized sale of GLP-1 weight-loss drugs amid rising generic variants. Inspections at online pharmacies, wholesalers, and clinics aim to prevent misuse that could lead to serious health risks. Patients must seek prescriptions only from qualified endocrinologists or specialists.
A veteran potato farmer in Lincolnshire is staring down a 'potato mountain' of 600 tons he can't sell, blaming weight-loss drugs like Ozempic and Mounjaro. With key buyer McCain not ordering, Andy Goodacre links the surplus to slimmer appetites from GLP-1 meds. Fish friers confirm the trend is hitting chip shops too.
